{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 414591272
| IUPAC_name = ''N''-benzyl-''N''-methylprop-2-yn-1-amine
| image = Pargyline.svg
| alt = Skeletal formula of pargyline
| image2 = Pargyline-3D-balls.png
| alt2 = Ball-and-stick model of the pargyline molecule

<!--Clinical data-->
| tradename =  
| MedlinePlus = a682088
| pregnancy_category =  
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7262
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 555-57-7
| ATC_prefix = C02
| ATC_suffix = KC01
| ATC_supplemental =  {{ATC|C02|LL01}}
| PubChem = 4688
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01626
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4526
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9MV14S8G3E
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 673

<!--Chemical data-->
| C=11 | H=13 | N=1
| molecular_weight = 159.23 g/mol
| smiles = C#CCN(C)Cc1ccccc1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DPWPWRLQFGFJFI-UHFFFAOYSA-N
}}

'''Pargyline''' (brand name '''Eutonyl''') is an irreversible selective [[monoamine oxidase]] (MAO)-B [[monoamine oxidase inhibitor|inhibitor]] drug ([[IC50|IC<sub>50</sub>]] for [[Monoamine oxidase A|MAO-A]] is 0.01152 µmol/L and for [[Monoamine oxidase B|MAO-B]] is 0.00820 µmol/L)<ref name="pmid21200377">{{cite journal |vauthors=Fisar Z, Hroudová J, Raboch J |title=Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. |journal=Neuro Endocrinol Lett. |volume=31 |issue=5 |pages=645–56|year=2010 |pmid=21200377}}</ref><ref name="pmid9564606">{{cite journal  |vauthors=Murphy DL, Karoum F, Pickar D, etal |title=Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline) |journal=J. Neural Transm. Suppl. |volume=52 |issue= |pages=39–48 |year=1998 |pmid=9564606 |doi= 10.1007/978-3-7091-6499-0_5|url=}}</ref> It was brought to market in the US and the UK by [[Abbott Laboratories|Abbott]] in 1963 as  an [[Antihypertensive drug|antihypertensive]] drug branded "Eutonyl". It was one of several MAO inhibitors introduced in the 1960s including [[nialamide]], [[isocarboxazid]], [[phenelzine]], and [[tranylcypromine]].<ref>Edward Shorter, A historical dictionary of psychiatry.  Oxford University Press, Inc 2005. {{ISBN|0195176685}}</ref>{{rp|146}}<ref>William M. Wardell and Louis Lasagna. Regulation Drug Development (Evaluative Studies 21) American Enterprise Institute (1975)  {{ISBN|0844731676}}</ref>{{rp|60}}<ref>Council on Drugs [http://jama.jamanetwork.com/article.aspx?articleid=665676 New Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl)] JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013.</ref><ref>{{Cite journal|title = Eutonyl and MAO inhibitors|url = http://dtb.bmj.com/content/1/15/59|journal = Drug and Therapeutics Bulletin|date = 15 November 1963|issn = 1755-5248|pages = 59–60|volume = 1|issue = 15|doi = 10.1136/dtb.1.15.59|language = en|quote = Pargyline is promoted only for the treatment of hypertension, and not for depression.}}</ref> By 2007 the drug was discontinued<ref>W. Steven Pray [http://www.medscape.com/viewarticle/566743_2 Interactions Between Nonprescription Products and Psychotropic Medications] US Pharmacist. 2007;32(11):12-15.</ref> and as of 2014 there were no generic versions available in the US.<ref>FDA [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=EUTONYL Eutonyl in the Drugs@FDA Database] Accessed July 19, 2014</ref> In addition to its actions as an MAOI, pargyline has been found to bind with high [[affinity (pharmacology)|affinity]] to the [[Imidazoline receptor|I<sub>2</sub> imidazoline receptor]] (an [[allosteric site]] on the MAO [[enzyme]]).<ref>{{cite book|title=Critical Reviews in Neurobiology|url=https://books.google.com/books?id=EP9FAQAAIAAJ|year=1995|publisher=CRC Press|page=43}}</ref>

==See also==
* [[Clorgyline]]
* [[Rasagiline]]
* [[Selegiline]]

==References==
{{Reflist|30em}}

{{Antihypertensives and diuretics}}
{{Antiparkinson}}
{{Monoamine metabolism modulators}}

[[Category:Abandoned drugs]]
[[Category:Alkynes]]
[[Category:Amines]]
[[Category:Antihypertensive agents]]
[[Category:Benzyl compounds]]
[[Category:Disulfiram-like drugs]]
[[Category:Monoamine oxidase inhibitors]]


{{antihypertensive-stub}}
{{nervous-system-drug-stub}}